Roche signed an R&D agreement on cancer research worth $1 billion

   Date:2013/11/14     Source:

Roche (RHHBY) signs an R&D collaboration agreement with immatics for cancer vaccines and immunotherapies "targeting primarily gastric, prostate, and non-small cell lung cancer."

immatics gets an upfront payment of $17M and is eligible for milestone payments up to and above $1B. immatics will also receive royalties on any marketed drugs.

2005-2014 All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号